The impact of initial highly active antiretroviral therapy on future treatment sequences in HIV infection

AIDS
Marina B KleinRichard G Lalonde

Abstract

To determine whether the initial use of non-nucleoside reverse transcriptase inhibitors (NNRTI) or protease inhibitors (PI) differentially influences subsequent HIV therapy. A cohort study using a prospective clinical database in a university-based HIV clinic. A total of 440 HIV-seropositive patients, naive or nucleoside experienced, initiating therapy with either an NNRTI or PI between January 1998 and July 2003 and followed to December 2003. Time until stopping the first regimen and until exposure to all antiretroviral classes (excluding tenofovir and enfuvirtide) according to the type of initial regimen. A total of 291 subjects initiated HAART with PI and 149 with NNRTI; median follow-up 3.1 and 2.3 years, respectively. Subjects starting NNRTI remained on their initial regimens longer (median time to change 2.1 versus 1.6 years; log rank P = 0.03). Overall, subjects initiating NNRTI-based regimens were less likely to alter their therapy. Previous nucleoside exposure was an important predictor of treatment modification. Subjects initiating NNRTI-based HAART were also less likely to experience virological failure than those initiating PI-based HAART. Individuals starting with NNRTI were exposed to fewer regimens (15 versus 25%...Continue Reading

References

Aug 10, 2000·Journal of Acquired Immune Deficiency Syndromes : JAIDS·T BiniA d'Arminio Monforte
Jul 4, 2001·Annals of Internal Medicine·E L MurphyUNKNOWN Viral Activation Transfusion Study Investigators
Aug 11, 2001·The New England Journal of Medicine·M A AlbrechtUNKNOWN AIDS Clinical Trials Group 364 Study Team

❮ Previous
Next ❯

Citations

Feb 17, 2010·International Journal of Epidemiology·Alexis K PalmerUNKNOWN CANOC Collaboration
Mar 22, 2015·Expert Review of Molecular Diagnostics·Nitika Pant Pai, Jana Daher
Jul 12, 2005·Expert Opinion on Investigational Drugs·Donglei YuKuo-Hsiung Lee
Mar 30, 2005·Expert Opinion on Drug Safety·David NolanSimon Mallal
Dec 7, 2005·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·David Nolan
Jun 18, 2010·Enfermedades infecciosas y microbiología clínica·UNKNOWN Panel de Expertos de Gesida, UNKNOWN Plan Nacional sobre el Sida
Dec 1, 2008·Enfermedades infecciosas y microbiología clínica·Joaquín PortillaSergio Reus
Feb 24, 2012·The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases·Flávia Andrade RibeiroDirceu Bartolomeu Greco

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.